GMDA Gamida Cell Ltd.

2.99
+0.2  (+7%)
Previous Close 2.79
Open 2.8
Price To Book 2.88
Market Cap 100,676,069
Shares 33,670,926
Volume 22,012
Short Ratio
Av. Daily Volume 23,935
Stock charts supplied by TradingView

NewsSee all news

  1. New Directors Elected to BiondVax's Board of Directors

    JERUSALEM, March 24, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the

  2. Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow Transplantation

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that updated results from a Phase 1 clinical study of GDA-201, an

  3. Gamida Cell Reports Full Year 2019 Financial Results and Provides Company Update

    – Completed patient enrollment in Phase 3 clinical study of omidubicel; Topline data expected in the second quarter of 2020 – – Company to host conference call at 8:30 a.m. ET today – Gamida Cell Ltd. (NASDAQ:GMDA),

  4. Gamida Cell Announces the Date of Its Full Year 2019 Financial Results and Webcast

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on

  5. Gamida Cell Announces 2020 Goals and Provides Company Update

    – Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing with additional data expected in first half of 2020 – – Jas Uppal, Ph.D., appointed as chief regulatory

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 trial ongoing.
NAM-NK (GDA-201)
Non-Hodgkin lymphoma; Multiple myeloma
Phase 1/2 data due 2H 2020.
NiCord (omidubicel)
Severe aplastic anemia
Phase 3 top-line data due 2Q 2020.
NiCord (omidubicel)
Acute myeloid leukemia

Latest News

  1. New Directors Elected to BiondVax's Board of Directors

    JERUSALEM, March 24, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the

  2. Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow Transplantation

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that updated results from a Phase 1 clinical study of GDA-201, an

  3. Gamida Cell Reports Full Year 2019 Financial Results and Provides Company Update

    – Completed patient enrollment in Phase 3 clinical study of omidubicel; Topline data expected in the second quarter of 2020 – – Company to host conference call at 8:30 a.m. ET today – Gamida Cell Ltd. (NASDAQ:GMDA),

  4. Gamida Cell Announces the Date of Its Full Year 2019 Financial Results and Webcast

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on

  5. Gamida Cell Announces 2020 Goals and Provides Company Update

    – Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing with additional data expected in first half of 2020 – – Jas Uppal, Ph.D., appointed as chief regulatory

  6. Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel

    – Topline data expected in first half of 2020 – Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the

  7. Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual Meeting

    — GDA-201 demonstrated early evidence of clinical activity in patients with non-Hodgkin lymphoma, with multiple complete responses observed — — Research on mechanism of action for the NAM technology platform provides

  8. Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company's chief executive officer,

  9. Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company Update

    – Completion of patient enrollment in Phase 3 clinical study of omidubicel expected by year-end; Topline data anticipated in first half of 2020 – – Additional results from Phase 1 study of GDA-201 and new data on NAM

  10. Gamida Cell Announces Data to be Presented at ASH 2019 Annual Meeting

    – Presentations to include updated results from Phase 1 study of GDA-201 and new data on mechanism of action for NAM cell expansion platform – Gamida Cell Ltd. (NASDAQ:GMDA), a leading cellular and immune therapeutics

  11. Gamida Cell Announces the Date of Its Third Quarter 2019 Financial Results and Webcast

    Gamida Cell Ltd. (NASDAQ:GMDA), a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Wednesday, November 13, 2019, at 4:30 p.m. ET to

  12. Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

    – Multi-Year Observational Study Designed to Evaluate Outcomes of Patients with Hematologic Malignancies Who Undergo Allogeneic Bone Marrow Transplantation – Gamida Cell Ltd. (NASDAQ:GMDA), a leading cellular and